NL-OMON33904已完成不适用
A PHASE I, SINGLE-CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, SINGLE- AND MULTIPLE ASCENDING-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF GRC 10693 IN HEALTHY MALE SUBJECTS - A Phase I to study GRC 10693 in Healthy Male Subjects.
Glenmark Pharmaceuticals SA.0 个研究点目标入组 96 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 96
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Subjects must be Caucasian males, 18-45 years of age, inclusive;
- •2. Subjects must voluntarily sign a written informed consent agreement;
- •3. Subjects must be in good health, based upon the results of medical history, physical examination, electrocardiogram (ECG) and laboratory profiles of both blood and urine.;For the first cohort of the MAD study, in addition to the inclusion criteria as given above in D4, the following applies and/or overrides the corresponding exclusion criterion for the SAD study
- •1. Subjects who were administered a single dose of GRC 10963 in the SAD stage of the study may be enrolled.
- •2. Subjects who have turned 46 years of age since their participation in the SAD study may be enrolled.;Recruitment criteria of subjects for subsequent cohorts in the MAD stage may be equivalent to criteria of cohorts in SAD stage (after review of the results of the previous SAD and MAD cohort(s)).
排除标准
- •1. Subjects who smoke (subjects will have to be non-smokers for at least 6 months preceding screening);
- •2. Subjects with active presence or history of alcoholism or drug addiction;
- •3. Subject who had an operation in the within 3 months prior to the (first) dosing day;
- •4. Subjects who have used over-the-counter medication (including homeopathic medicines and vitamins), within 96 hours (h) prior to the dosing day, with the exception of paracetamol, which is allowed at the discretion of the PI;
- •5. Subjects who have used prescription medication within 2 weeks prior to the first dosing day;
- •6. Subjects who have participated in an investigational drug study within 3 months prior to the dosing day;
- •7. Subjects who have lost or donated >350 ml of blood within 12 weeks prior to the (first) dosing day;
- •8. Subjects who test positive for hepatitis B, C or HIV;
- •9. Subjects who are considered unsuitable to participate in the study for any reason in the opinion of the PI.;For the first cohort of the MAD study, next to the exclusion criteria as given above in D5, the following applies and/or overrides the corresponding exclusion criterion for the SAD study:
- •1. Subjects who have participated in an investigational drug study except the SAD study of GRC 10963 within 3 months prior to the dosing day;
- •2. Subjects who have participated in the SAD stage of the study and whose exposure to GRC 10693 in terms of Cmax¬ and/or AUC0 * was more than two times the median value for the dose group, and/or whose terminal elimination half-life exceeded 52 hours.
- •3. Subjects who were administered a single dose of GRC 10963 in the SAD stage of the study may be enrolled with a Body Mass Index (BMI) <18.0 or >30.0 kg/m2;Exclusion criteria of subjects for subsequent cohorts in the MAD stage may be equivalent to criteria of cohorts in SAD stage (after review of the results of the previous SAD and MAD cohort(s)).
研究者
相似试验
已完成
不适用
A PHASE I, SINGLE CENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, SINGLE DOSE STUDY IN HEALTHY FEMALE AND ELDERLY VOLUNTEERS AND MULTIPLE ASCENDING DOSE STUDY IN HEALTHY MALE AND FEMALE VOLUNTEERS BETWEEN THE AGES OF 18-80 YEARS TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF GRC 17536Astma, COPD, hoesten, chronische pijnCOPDAsthmaNL-OMON38062Glenmark Pharmaceuticals SA74
进行中（未招募）
不适用
A PHASE 2, SINGLE-CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF ZOLEDRONATE IN SUBJECTS WITH EROSIVE HAND OSTEOARTHRITIS - ZOLEHOErosive hand osteoarthritisMedDRA version: 12.1Level: LLTClassification code 10019115Term: Hand osteoarthritisEUCTR2010-019110-24-DEniversitätsklinikum Erlangen
已完成
1 期
oribogaine Therapy for Relief of Opioid withdrawal, Phase 1BSymptoms of opioid withdrawalMental Health - AddictionACTRN12613001064796DemeRx Inc27
已完成
不适用
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RG2459 IN HEALTHY VOLUNTEERS, INCLUDING A SINGLE DOSE PROOF-OF-CONCEPT PART IN PATIENTS INFECTED WITH HEPATITIS C VIRUS, AND A DRUG INTERACTION PART WITH SIMEPREVIR (TMC435) IN HEALTHY VOLUNTEERSHepatitic C virus infection10047438Hepatitis CNL-OMON41383Regulus Therapeutics Inc.108
已完成
1 期
A PHASE I, TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF RAY121 IN HEALTHY VOLUNTEERSHealthy VolunteerJPRN-jRCT2071220036Kai Megumi40